Multidrug resistance-associated protein - reduction of expression in human leukaemia cells by antisense phosphorothioate oligonucleotides

• Autorzy: Niewiarowski W. , Gendaszewska E. , Rebowski G. , Wojcik M. , Mikolajczyk B. , Goos W. , Soszynski M. , Bartosz G.
• Języki publikacji: EN

Abstrakty

EN

Multidrug resistance-associated protein (MRP1) causes cellular drug resistance in several cancer cell lines. In this paper we show that antisense oligonucleotides decrease MRP1 expression in human leukaemia cells. We investigated biological activity of a series of 12 linear phosphorothioate oligonucleotides, complementary to several regions of MRP1 mRNA. The oligonucleotides were administered to leukaemia HL60/ADR cells overexpressing MRP1 protein. Then, the level of MRP1 mRNA was determined by means of semiquantitative RT-PCR and the protein level by reaction with specific monoclonal antibodies. Some of the investigated antisense oligonucleotides decrease the expression level of the MRP1 protein by 46% and its mRNA level by 76%.

Słowa kluczowe

EN

multidrug resistance; drug resistance; cell line; antisense oligonucleotide; man; leukemic cell; cancer; oligonucleotide

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2000
• Tom: 47
• Numer: 4
• Opis fizyczny: p.1183-1188,ref.

Twórcy

autor

Niewiarowski W.

• Polish Academy of Sciences, H.Sienkiewicza 112, 90-363 Lodz, Poland

autor

Gendaszewska E.

autor

Rebowski G.

autor

Wojcik M.

autor

Mikolajczyk B.

autor

Goos W.

autor

Soszynski M.

autor

Bartosz G.

Bibliografia

• 1. Zaman, G.J.R., Flens M.J., Leusden van, M.R., Haas de, M., Mulder, H.S., Lankelma, J., Pinedo, H.M., Scheper, R.J., Baas, F., Broxterman, H.J. & Borst, P. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 8822-8826.
• 2. Almquist, K.C., Loe, D.W., Hipfner, D.R., Mackie, J.E., Cole, S.P.C. & Deeley, R.G. (1995) Canc. Res. 55, 102-110.
• 3. Bartosz, G. (1998)Post. Biochem. 44, 136-151 (in Polish).
• 4. Broxterman, H.J., Lankelma, J. & Pinedo, H.M. (1996) Eur. J. Canc. 32A, 1024-1033.
• 5. Loe, D.W., Deeley, R.G. & Cole, S.P.C. (1998) Canc. Res. 58, 5130-5136.
• 6. Rappa, G., Lorico, A., Flavell, R.A. & Sar- torelli, A.C. (1997) Canc. Res. 57, 5232-5237.
• 7. Loe, D.W., Deeley, R.G. & Cole, S.P.C. (1996) Eur. J. Canc. 23A, 945-957.
• 8. Nooter, K., Burger, H. & Stoter, G. (1996) Leuk. Lymphoma 20, 381-387.
• 9. Stewart, A.J., Canitrot, Y., Baracchini, E., Dean, N.M., Deeley, R.G. & Cole, S.P.C. (1996) Biochem. Pharmacol. 51, 461-469.
• 10. Zamecnik, P.C. & Stevenson, M.L. (1978) Proc. Natl. Acad. Sci. U.S.A. 75, 280-294.
• 11. Agrawal, S. & Zhao, Q. (1998) Curr. Opin. Chem. Biol. 2, 519-528.
• 12. Crook, R.M. (1996) Handbook of Experimental Pharmacology: Antisense Research and Applica­tion (Crooke, S.T., ed) 131, 103-140, Springer-Verlag, Berlin, Heidelberg, New York.
• 13. Caucco, C. & Calabretta, B. (1996) Canc. Res. 56, 4332-4337.
• 14. Kool, M., de Haas, M., Sheffer, G.L., Scheper, R.J., van Eijk, M.J., Juijn, J.A., Baas, F. & Borst, P. (1997) Canc. Res. 57, 3537-3547.
• 15. Stec, W.J., Zon, G., Egan, W. & Stec, B. (1984) J. Am. Chem. Soc. 106, 6077-6080.
• 16. Stec, W.J., Uznanski, B., Wilk, A., Hirschbein, B.L., Fearon, K.L. & Bergor, B.J. (1993) Tetra­hedron Lett. 34, 5317-5320.
• 17. Lowry, J.O.H., Rosebrough, N.J., Farr, R.L. & Randal, R.J. (1951) J. Biol. Chem. 193, 265-275.
• 18. Laemmli, U.A. (1970) Nature 227, 680-683.
• 19. Agrawal, S. (1996) Trends Biotech. 14, 376­387.
• 20. Nicklin, P.L., Craig, S.J. & Philips, J.A. (1998) W. Niewiarowski and others in Handbook of Experimental Pharmacology: Antisense Research and Application (Crooke, S.T., ed.) 131, 141-168, Springer-Verlag, Berlin, Heidelberg, New York.